spot_img
Monday, November 16, 2026

Johnson & Johnson to acquire Ollin Biosciences in $2.2B deal, taps Blackstone to fund Phase 3 trials

Johnson & Johnson announced Monday it has entered into a definitive agreement to acquire clinical-stage biopharmaceutical firm Ollin Biosciences, Inc. for $2.2 billion upfront—plus up to $1.125 billion in potential milestones—in a major push to bolster its ophthalmology pipeline.

Contingent upon the closing of the acquisition, which is expected before the end of 2026, the New Brunswick-based healthcare giant will also enter into a separate $750 million multi-year research and development funding agreement with Blackstone Life Sciences to fully finance Phase 3 clinical trials for Ollin’s lead candidate, OLN324.

The acquisition centers on OLN324, an investigational Phase 3 bispecific antibody engineered to treat retinal vascular diseases, including age-related macular degeneration (AMD) and diabetic macular edema (DME)—conditions that collectively affect more than 40 million people globally and rank among the leading causes of vision loss.

Designed with a small “minibody” protein format and high angiopoietin-2 (Ang2) potency, OLN324 simultaneously targets two primary drivers of retinal disease: vascular endothelial growth factor (VEGF) and Ang2. According to Johnson & Johnson, the dual-targeting mechanism is designed to achieve superior retinal fluid control and extend the interval required between patient eye injections compared to existing therapies.

“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control,” Kip Connor, vice president and ophthalmology disease area stronghold leader at Johnson & Johnson said. “The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.”

While Johnson & Johnson maintains a strong commercial presence in vision care through its Acuvue contact lenses and Tecnis intraocular surgical lenses, the deal marks a significant rebuilding of its pharmaceutical retina pipeline following clinical setbacks earlier in 2026 involving gene therapy candidates. With OLN324, J&J positions itself to compete directly in a multi-billion-dollar market currently dominated by Roche’s bispecific antibody Vabysmo and Regeneron’s Eylea.

Key financial terms of the two-part transaction include:

  • Ollin Acquisition: Johnson & Johnson will pay $2.2 billion in upfront cash, with Ollin shareholders eligible to receive up to approximately $1.125 billion in additional regulatory and commercial milestone payments—bringing the potential total deal value to $3.325 billion.
  • Blackstone R&D Financing: Upon deal close, Blackstone Life Sciences will provide $750 million over multiple years to cover the full cost of Phase 3 development for OLN324.In exchange, Blackstone will be eligible for certain regulatory and commercial milestones as well as single-digit royalties on future net sales.

Completion of the acquisition remains subject to customary closing conditions and applicable regulatory approvals, with Johnson & Johnson noting that accounting treatment details will be communicated on or before the transaction closes later this year.

+ posts

Get the Latest News

Sign up to get all the latest news, offers and special announcements.

Get our Print Edition

All the latest updates, delivered.

Latest Posts

Get the Latest News

Sign up to get all the latest news, offers and special announcements.

Get our Print Edition

All the latest updates, delivered.